Peptide Comparison
Ipamorelin vs Hexarelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
Two GHRPs in the same regimen: Moderate risk per peptide research literature. Ghrelin receptor (GHS-R1a) saturation + accelerated desensitization; may blunt long-term GH response.
Data-derived verdict
Ipamorelin and Hexarelin share the ghrp / gh-secretagogue classes and carry roughly equivalent evidence (Anecdotal + Phase 2 / Phase 2 (not approved)). On the catalogued data layer Ipamorelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Ipamorelin's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Ipamorelin | Hexarelin | |
|---|---|---|
| Class | Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist | GHRP; potent ghrelin receptor agonist |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise | GHS-R1a agonist; more potent GH release than other GHRPs |
| Route | SC injection | SC / Intranasal |
| Half-life | ~2 hrs | ~1 hr |
| Dosage (research) | 200 mcg SC 2x daily (Seeds Vol 1 starting protocol, range up to 300 mcg 3x daily per r/Peptides wiki, often stacked with CJC-1295 no-DAC) | 100-200 mcg SC 1-2x daily (short cycles) |
| Evidence tier | Anecdotal + Phase 2 | Phase 2 (not approved) |
| Research depth | 91 indexed | 196 indexed |
| Availability | Compounding Restricted | Research Chemical |
| Reported risks | Mild fatigue; headache; injection site reactions; elevated IGF-1 theoretical | Cortisol/prolactin elevation; pituitary desensitization |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Ipamorelin or Hexarelin?
Ipamorelin and Hexarelin share the ghrp / gh-secretagogue classes and carry roughly equivalent evidence (Anecdotal + Phase 2 / Phase 2 (not approved)). On the catalogued data layer Ipamorelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Ipamorelin's evidence base is currently denser.
What is the difference between Ipamorelin and Hexarelin?
Ipamorelin is classed as Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist; Hexarelin is classed as GHRP; potent ghrelin receptor agonist. Reported mechanism: Ipamorelin, Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise; Hexarelin, GHS-R1a agonist; more potent GH release than other GHRPs. Reported half-life: Ipamorelin, ~2 hrs; Hexarelin, ~1 hr. Routes in published studies: Ipamorelin, SC injection; Hexarelin, SC / Intranasal.
Which has stronger evidence, Ipamorelin or Hexarelin?
Ipamorelin and Hexarelin sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Ipamorelin is graded Anecdotal + Phase 2, with 9 cited sources on its reference page and 91 indexed studies. Hexarelin is graded Phase 2 (not approved), with 4 cited sources on its reference page and 196 indexed studies.
Which is more accessible, Ipamorelin or Hexarelin?
Neither Ipamorelin nor Hexarelin is an FDA-approved drug. Catalog status: Ipamorelin, Compounding Restricted; Hexarelin, Research Chemical. FDA lists Ipamorelin in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).
Are Ipamorelin and Hexarelin ever combined?
Ipamorelin and Hexarelin appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two GHRPs in the same regimen, moderate risk.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…